The fact that patients with the coronavirus that were treated with anti-malarial drugs, there are side effects — not surprisingly. They were given too high doses patients in serious condition, said in an interview with Znak.com Professor of internal medicine Department of the Russian University of peoples ‘ friendship, doctor of medical Sciences Natalia Kozlovskaya. “It’s the drugs not from СOVID, they are designed for the treatment of malaria. Patients are given doses that are much higher are allowed to use that, I think, presumably, is related to the epidemiological situation,” she said, adding that the drugs were administered at doses higher than therapeutic, and patients in serious condition. “It is a law of medicine that the heavier a person is sick, the greater the risk of adverse events,” explained the Professor. She emphasized that any drug must be administered when it is really needed — in the early stages, “but in any case, when there is disease affecting the lungs.” Kozlovskaya said that categorically speak that these drugs cannot be assigned to anyone, is a bit premature. However, to take these drugs for the prevention COVID-19 is pointless. “The mechanism of action of this drug — it inhibits the penetration of the virus into the cell. If the human virus is not infiltrated, why would he want to expose yourself to any whatsoever of the drug. If a virus has been introduced, it would probably be the correct drug is administered to that day when the first man was found with the virus. But since this is impossible to guess, better not to risk it,” said Kozlovskaya. She stressed that her statements have a General biological nature, it does not work with patients with confirmed coronavirus infection. Earlier, Sunthe world health organization (who) has suspended clinical trials of anti-malarial drugs hydroxychloroquine and chloroquine as a potential cure for COVID-19. However, the organization stressed that these drugs “continue to be regarded as safe” for patients with malaria and autoimmune diseases. Meanwhile, last week the Ministry of health approved the transition to the final stage of the comparative clinical studies of the possible application of the drug “Favipiravir” for the treatment COVID-positive patients. The Russian direct investment Fund (RDIF) said that the drug performed well in treatment. However, earlier today it became known that Japanese specialists are unable to prove the effectiveness of the influenza drug “Avigan” (also known as “Favipiravir”) for the treatment of patients with coronavirus. As the Minister of health of Japan Katsunobu Kato, the Japanese government is expected to approve the drug as a medication for patients with coronavirus during the month of may, but the date of approval will be moved to more obvious results. As noted by an independent Committee, evaluated the results of the interim report, released in mid-may, to judge the effectiveness of the drug too early and need to continue testing.
Stories about how you tried to get help from the Russian state in terms of coronaries and what came of it, email it to COVID-19@rosbalt.ru
